News
Why 2023 could be the best—and worst—year for VCs in Asia
Venture capitalists see pickup deal activity, but expect difficulties in fundraising.
6 mins read
US
The pharmaceutical industry is no stranger to controversy.
Despite the current bearish sentiment, NFT adoption is likely to grow, driven by their utility.
President Biden hails manufacturing revival in America.
Regulation is coming.
Industry confidence battered by problems at one of biggest players.
Focus on few, higher-priced models puts EV maker in lead on net earnings.
SBG, other nontraditional investors squeeze money, prioritize profit.
VinFast is set to go public in the US in the second half of 2022, per Bloomberg.
